157 related articles for article (PubMed ID: 38216883)
21. K-RAS mutant pancreatic tumors show higher sensitivity to MEK than to PI3K inhibition in vivo.
Hofmann I; Weiss A; Elain G; Schwaederle M; Sterker D; Romanet V; Schmelzle T; Lai A; Brachmann SM; Bentires-Alj M; Roberts TM; Sellers WR; Hofmann F; Maira SM
PLoS One; 2012; 7(8):e44146. PubMed ID: 22952903
[TBL] [Abstract][Full Text] [Related]
22. Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines.
Vitiello PP; Cardone C; Martini G; Ciardiello D; Belli V; Matrone N; Barra G; Napolitano S; Della Corte C; Turano M; Furia M; Troiani T; Morgillo F; De Vita F; Ciardiello F; Martinelli E
J Exp Clin Cancer Res; 2019 Jan; 38(1):41. PubMed ID: 30691487
[TBL] [Abstract][Full Text] [Related]
23. Altered expression of mitogen-activated protein kinases in a rat model of experimental hepatocellular carcinoma.
McKillop IH; Schmidt CM; Cahill PA; Sitzmann JV
Hepatology; 1997 Dec; 26(6):1484-91. PubMed ID: 9397988
[TBL] [Abstract][Full Text] [Related]
24. Delicaflavone induces ROS-mediated apoptosis and inhibits PI3K/AKT/mTOR and Ras/MEK/Erk signaling pathways in colorectal cancer cells.
Yao W; Lin Z; Shi P; Chen B; Wang G; Huang J; Sui Y; Liu Q; Li S; Lin X; Liu Q; Yao H
Biochem Pharmacol; 2020 Jan; 171():113680. PubMed ID: 31669234
[TBL] [Abstract][Full Text] [Related]
25. Regulation of p21ras activity.
Lowy DR; Zhang K; DeClue JE; Willumsen BM
Trends Genet; 1991; 7(11-12):346-51. PubMed ID: 1820685
[TBL] [Abstract][Full Text] [Related]
26. Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers.
Temraz S; Mukherji D; Shamseddine A
Int J Mol Sci; 2015 Sep; 16(9):22976-88. PubMed ID: 26404261
[TBL] [Abstract][Full Text] [Related]
27. RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers.
Nichols RJ; Haderk F; Stahlhut C; Schulze CJ; Hemmati G; Wildes D; Tzitzilonis C; Mordec K; Marquez A; Romero J; Hsieh T; Zaman A; Olivas V; McCoach C; Blakely CM; Wang Z; Kiss G; Koltun ES; Gill AL; Singh M; Goldsmith MA; Smith JAM; Bivona TG
Nat Cell Biol; 2018 Sep; 20(9):1064-1073. PubMed ID: 30104724
[TBL] [Abstract][Full Text] [Related]
28. Negative feedback regulation and desensitization of insulin- and epidermal growth factor-stimulated p21ras activation.
Langlois WJ; Sasaoka T; Saltiel AR; Olefsky JM
J Biol Chem; 1995 Oct; 270(43):25320-3. PubMed ID: 7592690
[TBL] [Abstract][Full Text] [Related]
29. Role of p21 RAS in p210 bcr-abl transformation of murine myeloid cells.
Mandanas RA; Leibowitz DS; Gharehbaghi K; Tauchi T; Burgess GS; Miyazawa K; Jayaram HN; Boswell HS
Blood; 1993 Sep; 82(6):1838-47. PubMed ID: 7691239
[TBL] [Abstract][Full Text] [Related]
30. Platelet-derived growth factor stimulation of GTPase-activating protein tyrosine phosphorylation in control and c-H-ras-expressing NIH 3T3 cells correlates with p21ras activation.
Molloy CJ; Fleming TP; Bottaro DP; Cuadrado A; Aaronson SA
Mol Cell Biol; 1992 Sep; 12(9):3903-9. PubMed ID: 1508192
[TBL] [Abstract][Full Text] [Related]
31. Induction of postmitotic neuroretina cell proliferation by distinct Ras downstream signaling pathways.
Peyssonnaux C; Provot S; Felder-Schmittbuhl MP; Calothy G; Eychène A
Mol Cell Biol; 2000 Oct; 20(19):7068-79. PubMed ID: 10982823
[TBL] [Abstract][Full Text] [Related]
32. Biphasic activation of p21ras by endothelin-1 sequentially activates the ERK cascade and phosphatidylinositol 3-kinase.
Foschi M; Chari S; Dunn MJ; Sorokin A
EMBO J; 1997 Nov; 16(21):6439-51. PubMed ID: 9351826
[TBL] [Abstract][Full Text] [Related]
33. Paris saponin VII inhibits growth of colorectal cancer cells through Ras signaling pathway.
Li Y; Sun Y; Fan L; Zhang F; Meng J; Han J; Guo X; Zhang D; Zhang R; Yue Z; Mei Q
Biochem Pharmacol; 2014 Mar; 88(2):150-7. PubMed ID: 24462916
[TBL] [Abstract][Full Text] [Related]
34. Interaction of GTPase activating proteins (GAPs) with p21ras measured by a novel fluorescence anisotropy method. Essential role of Arg-903 of GAP in activation of GTP hydrolysis on p21ras.
Brownbridge GG; Lowe PN; Moore KJ; Skinner RH; Webb MR
J Biol Chem; 1993 May; 268(15):10914-9. PubMed ID: 8496156
[TBL] [Abstract][Full Text] [Related]
35. Mutational and nonmutational activation of p21ras in rat colonic azoxymethane-induced tumors: effects on mitogen-activated protein kinase, cyclooxygenase-2, and cyclin D1.
Bissonnette M; Khare S; von Lintig FC; Wali RK; Nguyen L; Zhang Y; Hart J; Skarosi S; Varki N; Boss GR; Brasitus TA
Cancer Res; 2000 Aug; 60(16):4602-9. PubMed ID: 10969813
[TBL] [Abstract][Full Text] [Related]
36. PC12 cell neuronal differentiation is associated with prolonged p21ras activity and consequent prolonged ERK activity.
Qui MS; Green SH
Neuron; 1992 Oct; 9(4):705-17. PubMed ID: 1382473
[TBL] [Abstract][Full Text] [Related]
37. Vincristine Enhances the Efficacy of MEK Inhibitors in Preclinical Models of KRAS-mutant Colorectal Cancer.
Ghosh S; Fan F; Powell RT; Roszik J; Park YS; Stephan C; Sebastian M; Tan L; Sorokin AV; Lorenzi PL; Kopetz S; Ellis LM; Bhattacharya R
Mol Cancer Ther; 2023 Aug; 22(8):962-975. PubMed ID: 37310170
[TBL] [Abstract][Full Text] [Related]
38. Protein kinase C delta is required for survival of cells expressing activated p21RAS.
Xia S; Forman LW; Faller DV
J Biol Chem; 2007 May; 282(18):13199-210. PubMed ID: 17350960
[TBL] [Abstract][Full Text] [Related]
39. A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors.
Loboda A; Nebozhyn M; Klinghoffer R; Frazier J; Chastain M; Arthur W; Roberts B; Zhang T; Chenard M; Haines B; Andersen J; Nagashima K; Paweletz C; Lynch B; Feldman I; Dai H; Huang P; Watters J
BMC Med Genomics; 2010 Jun; 3():26. PubMed ID: 20591134
[TBL] [Abstract][Full Text] [Related]
40. Concomitant inhibition of receptor tyrosine kinases and downstream AKT synergistically inhibited growth of KRAS/BRAF mutant colorectal cancer cells.
Song Q; Sun X; Guo H; Yu Q
Oncotarget; 2017 Jan; 8(3):5003-5015. PubMed ID: 28002807
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
